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Abstract
The aim of this study was to evaluate the local immune status of human ovarian cancers 
by the comprehensive analysis of tumor-infiltrating immune cells and 
immunosuppressive factors, and to elucidate the local immunity in clinical course. The 
numbers of CD1 +, CD4+, CD8+, CD57+, forkhead box P3+ and programmed cell 
death-1+ cells were counted, and the intensity of immunosuppressive factors, such as 
programmed cell death-1 ligand (PD-L)1 , PD-L2, cyclooxygenase (COX)-1, COX-2
and 1, were evaluated in 70 ovarian cancer specimens
stained by immunohistochemistry. Then hierarchical clustering of these parameters
showed the four clusters into ovarian cancer cases. Cluster 1, which had significantly 
better prognosis than the others, was characterized by high infiltration of CD4+ and
CD8+ cells. In conclusion the comprehensive analysis of local immune status led to 
subdivide ovarian cancers into groups with better or worse prognoses and may guide
precise understanding of the local immunity. 
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1. Introduction
Ovarian cancer is the most lethal gynecologic cancer in the world with 
>200,000 patients diagnosed every year and over a half of them dying annually. These 
deaths are partly due to the fact that more than half of the patients with ovarian cancer 
are diagnosed at advanced tumor stages (stage III or IV). Although platinum or 
taxane-based chemotherapies are effective in the treatment of the majority of ovarian 
cancer cases, most of the patients suffer from recurrence and eventually develop 
chemo-resistance. Considering the high mortality rate of ovarian cancer due to the 
absence of curative treatment in the advanced stage or at recurrence, new therapeutic 
modalities other than chemotherapy and surgery are urgently needed [1; 2; 3].
Tumor immune therapy has long been considered as an alternative modality in 
the treatment of solid tumors including ovarian cancer. Nevertheless, there have been 
few reports on clinically successful immune therapies. The failure in immune therapies 
in such clinical trials is partly ascribed to the phenomenon designate
that the dynamic interaction between 
tumor cells and immune cells in the local microenvironment plays a pivotal role in 
cancer development and progression [4]. In the case of advanced cancers, tumor cells 
establish an immunosuppressive environment regionally and make it difficult to induce 
immune activation to eliminate cancer cells. In this situation, adoptive immunotherapy, 
such as a tumor vaccine, is not sufficient to eradicate tumors [5; 6].
The differences in the phenotypes or populations of tumor-infiltrating immune 
cells, such as CD4+ (helper) T cells, CD8+ (cytotoxic) T cells, CD57+ (NK) cells and 
CD11c+ (dendritic) cells, have been shown to be associated with different clinical 
outcomes of solid tumors including colorectal cancer [7], breast cancer [8], gastric 
cancer [9; 10], lung cancer [11; 12], hepatic cancer [13; 14], melanoma [15], kidney 
cancer [16] and uterine cervical cancer [17]. In ovarian cancer, several recent studies 
have shown an association between tumor-infiltrating immune cells and clinical 
outcomes [18; 19]. We also reported that CD8+ T cell infiltration [20] and NK cell 
infiltration [21] are associated with a favorable prognosis in the ovarian cancer patient. 
On the other hand, regulatory T cells, most specific marker of which is FOXP3, in the 
tumor site play a suppressive role in the local tumor immunity, leading to tumor 
progression [22; 23].
With respect to the tumor, there are also a wide variety of mechanisms that 
enable tumor cells to evade an immune attack. These mechanisms include a loss of 
MHC [24], the upregulation of immunosuppressive factors, such as transforming 
( ) [25], IL-10, indoleamine 2,3-dioxygenase (IDO) [26] and 
cyclooxygenases (COX-1 and COX-2) [27] or upregulating negative regulatory signals,
such as programmed cell death-1 (PD-1) ligands (PD-L1, PD-L2) and cytotoxic T 
lymphocyte antigen-4 (CTLA-4) [28; 29; 30; 31]. We reported that PD-L1 expression in 
ovarian cancer is inversely correlated with tumor-infiltrating CD8+ T cells and is 
associated with a poor prognosis of the patient [20]. The expression of the immune 
suppressive factors COX and UL-16 binding protein 2 is also inversely associated with
CD8+ T cell infiltration and the prognosis of the patient with ovarian cancer [21; 32].
Thus, there are a variety of reports that suggest that a certain immunosuppressive factor 
influences the local tumor immunity. However, there are few comprehensive analyses
that integrate various immune factors and evaluate the immune status as a whole.
Therefore, in this study, we attempted to explore the status of local immunity in 
ovarian cancers by integrating various immune parameters presented by the 
immunohistochemical analysis of clinical specimens. For this purpose, we employed 
bioinformatics analyses, such as hierarchical clustering, that allows the comprehensive 
assessment of multiple factors and enables us to determine the relationships among 
them.
2. Materials and Methods
2.1. Patients and Samples
 Formalin-fixed, paraffin-embedded specimens were obtained from 70 patients who 
underwent primary surgery for epithelial ovarian cancer at the Kyoto University 
Hospital. After surgery, all patients received platinum- and paclitaxel-based 
chemotherapy. The average age of the patients was 55 years old (range, 26- 78; standard 
deviation [SD], 11). At the end of the study, 29 (41%) patients had died from their 
disease, and 41 (59%) patients were alive. The mean follow-up period was 5 years 
(range, 0- 11; SD, 3.0). All 70 tissue specimens were collected under the approval of the 
Ethics Committee of the Kyoto University Hospital.
2.2 Immunohistochemistry
The primary antibodies and antigen retrieval methods are listed in Supplementary 
Table 1. Briefly, formalin-fixed, paraffin- -thick 
sections. The tissue sections were deparaffinized in xylene and dehydrated. For antigen 
CD4 staining, the samples were boiled in Tris-EDTA buffer 
(pH 9.0) in a pressure cooker. For FOXP3 and PD-1 staining, the samples were boiled 
in citrate buffer (pH 6.0) in a pressure cooker. To block endogenous peroxidase activity, 
all of the sections were treated with 100% methanol containing H2O2. Nonspecific 
binding of IgG was blocked using normal rabbit serum (Nichirei, Tokyo, Japan). The 
sections were incubated with a mouse anti- antibody (Ab) (clone 
TB21), anti-CD4 monoclonal Ab (clone 1F6), anti-FOXP3 monoclonal Ab (clone 
236A/E7) and PD-1 monoclonal Ab (clone NAT) overnight at 4 C. Then the sections
were incubated with biotinylated rabbit anti-mouse secondary Abs (Nichirei), followed 
by an incubation with a streptavidin-peroxidase complex solution. Signals were 
generated by incubation with 3, 3-diaminobenzidine. Finally, the sections were 
counterstained with hematoxylin and observed under a microscope. 
2.3. Evaluation of the specimens
Immune cells in the intraepithelial space were counted using a microscopic field 
at ×200 magnification (0.0625 mm2). Five areas with the most abundant infiltration of 
immune cells were selected, and an average count was calculated. The result was 
interpreted as negative when fewer than five cells per 0.0625 mm2 were observed and as 
was evaluated according to the intensity of the staining and scored as follows: 0, 
negative; 1, very weak expression; 2, moderate expression; and 3, strongest expression. 
Cases with scores of 0 or 1 were defined as the low-expression group, and cases with 
scores of 2 or 3 were defined as the high-expression group. Two independent 
gynecological pathologists examined the immunohistochemical slides without any prior 
information regarding the clinical history of the patients.
2.4. Hierarchical clustering and statistics
Hierarchical clustering analysis of our immunohistochemical data was performed 
using the software Cluster 3.0 that was originally designed for manipulating cDNA 
microarray data [33]. Following the instructions of the software, the eleven parameters 
(six tumor-infiltrating immune cells and five immune suppressive factors) were 
normalized, and a complete-linkage hierarchical clustering was conducted. The 
dendrogram and heat map were graphically viewed using Java TreeView [33]. Cluster 




cluster and various clinic-
was employed to analyze the associations among 11 immunological factors. Univariate 
analysis for overall survival was performed and evaluated with the log rank test, and 
Kaplan Meier curves were generated. A multivariate Cox proportional-hazard model 
was used to evaluate the independency of Cluster 1 as a prognostic factor. Two-sided P 
values of <0.05 were considered to be significant.
3. Results
3.1. Expression of immune-suppressive factors in ovarian cancer specimens and 
patient prognosis
Immunohistochemical expression of 1, PD-L1, PD-L2, COX-1 and COX-2 
were evaluated in 70 ovarian cancer tissues (Figure 1). High expression (score 2 or 3) of 
1 was observed in 22 cases (31.4%) and low expression (scored 0 or 1) was 
observed in 48 cases (68.6%). There was no correlation between the expression of these 
factors and clinicopathological characteristics such as age, histological type, FIGO stage, 
TNM classification, and residual tumor state (Supplementary Table 2) [20; 32].
The log rank test showed that the 5-year survival rate of patients with high 
expression of 1, COX-1 or COX-2 was not significantly different from the 
patients with low expression (Supplementary Figure 1). Only the high expression of 
PD-L1 was an independent worse prognostic factor, whereas PD-L2 expression was not 
related to patient prognosis [20]. 
3.2. Tumor-infiltrating immune cell count and prognosis
The number of tumor-infiltrating CD1 + (dendritic cells), CD4+ (helper T cells), 
CD8+ (killer T cells), CD57+ (NK cells), FOXP3+ (regulatory T cells) and PD-1+ 
immune cells was evaluated using the same 70 ovarian cancer specimens (Figure 1). 
The average numbers of these cells were shown in Supplementary Table 3, respectively. 
There was positive correlation between tumor-infiltrating FOXP3+ cells and several 
clinicopathological factors such as age, histology, tumor status and residual tumor, 
while there was no correlation between the number of CD4+, CD8+, CD57+ or PD-1+ 
cells and clinicopathological characteristics (Supplementary Table 4 and 5). 
A significant correlation was found between parameters below; CD4+ cell 
infiltration vs. CD8+ cell infiltration, COX-1 and COX-2 expression, CD4+ cell vs. 
PD-1+ cell infiltration, CD8+ cell vs. PD-1+ cell infiltration, CD57+ cell vs. PD-1+ cell 
infiltration), FOXP3 cell infiltration vs. PD-L2 expression and FOXP3 vs. CD4+ cell
infiltration (Supplementary Table 6), although a negative correlation between COX-1 vs. 
COX-2 expression, CD8+ cell infiltration vs. PD-L1 expression, CD8+ cell infiltration 
vs. COX-1 expression and CD8+ cell infiltration vs. COX-2 expression [20; 32].
The log rank test showed that the overall survival rate of patients with high levels 
of CD1 +, CD4+, CD57+, FOXP3+ or PD-1+ immune cells was not significantly
different from patients with low infiltration (Supplementary Figure 1), whereas a high 
infiltration of CD8+ cells was the only beneficial prognostic factor (p<0.001) [20].
Combination of any two factors such as CD8+ and PD-L1 low did not serve as a 
superior prognostic factor compared with single factor. Besides we found a higher ratio 
of CD8/FOXP3 in Cluster 1 than that in Cluster 2-4, although there was no statistic 
significance (mean ± SD, Cluster 1, 3.4±2.4 vs. Cluster 2-4, 1.9±1.9 ). 
3.3 The correlation among eleven immunological factors 
The correlation among eleven immunological factors (the expression of PD-L1, 
PD-L2, COX-1, COX-2 and 1 and the number of tumor-infiltrating immune cells 
expressing CD1 +, CD4+, CD8+, CD57+, FOXP3+ and PD-1+) was examined 
(Supplementary Table 6). The expression of PD-L1 or COX expression was negatively 
correlated with the number of CD8+ cells in the tumor site, respectively [20; 32]. In this 
study, we found that the number of CD4+ cells was positively correlated with the 
number of CD8+ cells (correlation coefficient (R=0.240; p=0.045) and FOXP3+ cells 
(R=0.410; p<0.001). In addition, the number of PD-1+ cells showed a positive 
correlation with the number of CD4+ cells (R=0.302; p=0.011), CD8+ cells (R=0.366; 
p=0.002) and CD57+ cells (R=0.365; p=0.002). The number of FOXP3+ cells was 
negatively correlated with PD-L2 expression (R=-0.262; p=0.028).
3.4. Evaluation of the local immune status by hierarchical clustering of immune 
factors in ovarian cancer
Hierarchical clustering analysis of the expression levels of five immune 
suppressive factors and the cell counts of the six tumor-infiltrating immune cells were 
used to divide the 70 ovarian cancers into 2 major clusters and subdivided one of the 
major clusters into three clusters, which were designated as Cluster 1 and Clusters 2, 3 
and 4, respectively (Figure 2). When Cluster 1 was compared to the other clusters 
(Clusters 2-4), it was characterized as having significantly higher immune cell 
infiltration, such as CD4+ cells (p=0.004), CD8+ cells (p<0.0001) and PD-1+ cells 
(p=0.0037), and as having lower expression of immunosuppressive factors such as 
1, PD-L1, PD-L2, COX-1 and COX-2 (Figures 3A-3C, 3F and 4). 
The characteristics of the other three clusters were relatively common in terms of 
low immune cell infiltration and partially high expression of immune suppressive 
factors with the following patterns: Cluster 2, high COX-1 expression (p<0.0001) and 
high CD57+ cell (NK cell) infiltration (p=0.0042); Cluster 3, high PD-L2 (p=0.0002), 
low FOXP3+ cells (p=0.0288) and low PD-1+ cell infiltration (p=0.011); and Cluster 4, 
low CD4+, low CD8+, low CD1 +, low CD57+, low PD-1, high PD-L1, high 1, 
and high COX-2 (Figures 3 and 4).
3.5. Univariate analysis and correlation between four clusters and 
clinicopathological factors
The Kaplan Meier curve and log rank test showed that the overall survival rate of 
patients in Cluster 1 was significantly better than those in the other clusters (5-year 
survival rate in Cluster 1 vs. Clusters 2-4, 84.6% vs. 55.2%; p=0.041) (Figure 5 and 
Table 1). The progression-free survival rate of patients in Cluster 1 was not significantly, 
but was relatively, better than other clusters (5-year survival rate of Cluster 1 vs. 
Clusters 2-4, 78.6% vs. 44.4%; p=0.061). 
There was no statistical correlation between the four clusters and the 
clinicopathological factors such as primary tumor status, lymph node metastasis, distant 
metastasis, residual tumor status, the age of the patient, histology, and adjuvant 
chemotherapy (Table 2). 
3.6. Multivariate analysis
Multivariate analysis showed that Cluster 1 was an independent favorable 
prognostic factor for overall survival (RR, 4.93) (Table 1). Other factors contributing to 
overall poor survival were tumor status (RR, 5.36), lymph node metastasis (RR, 2.78), 
and residual tumor status (RR, 5.86) (Table 1).
4. Discussion
Recent studies have shown that local tumor immunity is closely associated with 
clinical course of cancer patient, and several immunological factors, including CD8 T 
cell count shown in our previous study, serve as prognostic indicator. However, these 
analyses were mainly done using single factor or combination of several factors, and 
there are few papers which tried to clarify the immunological background by analyzing 
multiple immune factors simultaneously. The application of hierarchical clustering 
allowed us to manage the complex data sets of immunohistochemical staining with 
multiple antibodies [34; 35] and to identify new groups of patients with similar local 
immunological patterns that may be caused by similar consequences. Ovarian cancers
were divided into two groups, Cluster 1 and Clusters 2-4, by hierarchical clustering 
analysis according to the local immunological state. The patients in Cluster 1 had a 
significantly better prognosis than those in other clusters (p=0.041, Figure 5B). In this 
group, immune cells, including CD4+ cells, CD8+ cells and PD-1+ cells, were highly 
infiltrated into tumor sites compared to the other clusters (p=0.004, p<0.001 and 
p=0.0037, respectively), while the expression of 1, PD-L1, PD-L2, COX-1 and 
COX-2 were significantly low. In this group, PD-1+ cells may represent T cells in the 
late active phase [36], though its significance is to be clarified. Thus, Cluster 1 was 
characterized by high immune cell infiltration and low expression of all 
immunosuppressive factors studied (Figures 3 and 4), suggesting that host-tumor 
immunity in the tumor microenvironment is still maintained in this group, which may 
lead to the significantly better prognosis. Besides a ratio of CD8/FOXP3ratio in Cluster 
1 was higher than that in Cluster 2-4, although there was no statistic significance, which 
is a similar tendency to the previously published report [19].
Clusters 2-4 were characterized by a low level of immune cell infiltration and
high expression of immunosuppressive factors and had significantly worse prognoses 
than Cluster 1. Cluster 2 was characterized by a significantly high expression of COX-1, 
whereas Cluster 3 and 4 had significantly high expressions of COX-2 (p=0.0053 and 
p=0.0048, respectively). The immunoregulatory function of COX-2-induced 
prostaglandin E2 (PGE2) is known to be important in inducing immune tolerance in the 
tumor microenvironment [37]. Secreted from tumor cells, PGE2 alters the Th1/Th2 
balance, suppresses lymphocyte proliferation, and regulates the function of antigen 
presenting cells [37; 38]. There is a report that expression of COX-2 is an independent 
prognostic factor in human ovarian carcinoma [39]. Hence, high expression of COX-2 
in Cluster 3 and Cluster 4 may contribute to poorer prognosis associated with low CD8+ 
cell infiltration (Figures 3-5 and Supplementary Table 6). Similarly, COX-1 expression 
was inversely correlated with CD8+ cell infiltration in Cluster 2, which may partly 
explain the poor prognosis of Cluster 2. 
Cluster 3 was characterized by high PD-L2 expression and low PD-1+ cell 
infiltration and had a worse prognosis. We previously reported that the patient with high 
expression of PD-L2 had a tendency for poor prognosis, although the difference was not 
statistically significant. In this respect, high expression of PD-L2 may partly explain the 
poor prognosis of this group, possibly by negatively influencing the infiltration of CD8+, 
CD4+ and PD-1+ cells. Cluster 4 was characterized by high expression of PD-L1, 
1 and COX2 and low CD8+ cell infiltration. Previous studies on PD-L1 
expression in malignant tumors, such as in kidney, bladder, breast, gastric, pancreatic 
and ovarian cancer, have shown that PD-L1 has a negative impact on the survival of the 
patient [29]. In addition, PD-L1 expression was inversely correlated with intraepithelial 
infiltrating CD8+ T cells, suggesting that PD-L1 inhibits the intratumoral infiltration of 
CD8+ T cells. signaling has been implicated in tumor progression, metastasis and 
immunosuppression in the advanced tumor phase [25]. These results suggest that PD-1 
ligand and/or COX expression are associated with an unfavorable clinical outcome of 
the patient by influencing the local immune environment. 
Recently, three phases of cancer immunoediting, namely, eliminatio
[4; 6; 40], have been proposed. In the 
phase, innate and adaptive immune cells recognize and eliminate tumor cells by
immunosurveillance, protecting the host against cancer. In t
phase, ongoing tumor growth and immune surveillance enter into a dynamic balance 
with one another, yielding in a protracted period. In the last phase, the tumor 
avoids immune-mediated destruction and develops into a clinically apparent neoplasm
[4]. This hypothesis is mainly applied to the process of cancer development in which 
immunosurveillance is gradually impaired. However, in clinical situations, cancer 
patients sometimes experience an asymptomatic period coexisting with known cancer 
lesions, or even a spontaneous regression, without any medical interventions, suggesting 
that the balance between tumor growth and host immunity significantly influences the 
clinical course of cancer patients. Nevertheless, there have been few studies that
intended to comprehensively analyze the local immune status of each case, which would 
thereby establish the means to predict the clinical outcome. In this study, Cluster 1 may 
represent a phenotype of the phase, where immune cells infiltrate into the 
tumor site to eliminate the tumor. Clusters 2, 3 and 4 may be in in which 
the local immune environment has already fallen into an immunosuppressive status. For 
an effective immune therapy, an understanding of the immune status in each case is 
particularly important. This study provides a model to analyze the complicated immune 
reaction in a local tumor site. 
This study may also provide a future direction for order-made immunotherapy in
each ovarian cancer patient. Currently, therapeutic modalities to target specific
immunosuppressive factors are being developed. Blocking antibodies against PD-1
(MDX-1106) have been developed and are in Phase I clinical trials for advanced 
refractory malignancies [41]. Phase II and III clinical trials using selective COX2 
inhibitors, celecoxib and rofecoxib, in combination with a chemotherapeutic have 
shown a clinical benefit [42]. Clinical trials focusing on the inhibition of the 
signaling pathway by a monoclonal antibody or a small molecule inhibitor of the TGF
receptor I kinase are being performed. To select the most efficient single or combined 
immune targeting therapies, precise assessments with multiple immune parameters in 
each case is essential. 
In conclusion, hierarchical clustering of tumor-infiltrating immune cells and 
immunosuppressive factors was used to identify a subgroup of ovarian cancer patients 
with a better prognosis. This study also suggested that immunosuppressive factors might 
influence the pattern of tumor-infiltrating immune cells. The approach to 
comprehensively analyze multiple immune factors shown here may lead to a precise 
understanding of the local immune status and provide a tool for the application of 
immune therapies to treat ovarian cancer patients. 
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Table 1
Univariate and multivariate analysis demonstrating the independent risk factors,
including Cluster 1, on overall survival of patients with ovarian cancer (n = 70).








  Cluster 1 38 1 1
  Clusters 2-4 32 3.98 (1.04- 5.90 ) 4.93 (1.11- 21.76)
Tumor status <0.001 0.013
  pT1 + pT2 31 1 1
  pT3 39 7.90 (2.73-22.83) 5.36 (1.42- 20.20)
LN metastasis 0.003 0.041
  pN0 56 1 1
  pN1 14 3.24 (1.50- 7.00) 2.78 (1.04- 7.38)
Distant metastasis 0.047 0.122
  pM0 57 1 1
  pM1 13 2.28 (1.01- 5.16) 2.44 (0.79- 7.58)
Residual tumor <0.001 0.001
  Optimal 49 1 1
  Suboptimal 21 4.54 (2.17- 9.50) 5.86 (1.98- 17.34)
Histology 0.477 0.103
  Serous type 33 1.33 (0.59- 3.02) 3.27 (1.20- 8.93)
  Non-serous type 37 1 1
Chemotherapy 0.122 0.936
  Paclitaxel 31 1 1
  No paclitaxel 39 1.79 (0.86- 3.77) 1.03 (0.48- 2.23)
Age 0.486 0.562
  < 55 32 1 1
  ≥55 38 1. 31(0.62- 2.77) 1.268 (0.57- 2.83)
Table 2
Correlations between the four clusters and clinicopathological characteristics in 
ovarian cancer (n = 70)
n Cluster 1 Cluster 2 Cluster 3 Cluster 4 p
Age 0.922
<55 32 6 8 10 10
55 38 8 5 11 12
Stage 0.972
I 27 6 3 9 9
II 4 1 0 1 2
III 26 5 5 8 8
IV 13 2 5 3 3
Histology 0.672
Serous 33 7 9 8 9
Clear cell 22 5 2 9 6
Endometrioid 11 1 1 4 5
Mucinous 2 0 0 0 2
Others 2 1 1 0 0
Tumor status 0.889
pT1+pT2 31 6 4 10 11
pT3 39 8 9 11 11
LN metastasis 0.566
Positive 14 2 5 4 3
Negative 56 12 8 17 19
Distant metastasis 0.499
Positive 13 2 5 3 3
Negative 57 12 8 18 19
Residual tumor 0.773
  Optimal 49 10 7 16 16
  Suboptimal 21 4 6 5 6
Chemotherapy 0.965
  No paclitaxel 39 9 7 12 11









Immunohistochemical staining of human ovarian cancer tissue.
(A) Representative staining patterns of ovarian cancers with low expression or with 
high expression of immunosuppressive factors, such as TGFβ1, PD-L1, PD-L2, COX-1, 
and COX-2, are shown. (B) Representative staining patterns with low or high 
infiltrating immune cells, such as CD1α+, CD4+, CD8+, CD57+, FOXP3+ or PD-1+ 
cells, in the tumor site are shown. Original magnification; (A and B) x200. White bar, 
200 μm.
Figure 2
Graphic representation of the immune status of 70 ovarian cancer tissues. 
Patterns of immune status were classified into four clusters by hierarchical clustering 
based on six phenotype of immune cells, such as CD1α+, CD4+, CD8+, CD57+, 
FOXP3+ or PD-1+ cells, in the tumor site and five immunosuppressive factors, such as 
TGFβ1, PD-L1, PD-L2, COX-1 and COX-2. Separated clusters are indicated by 
dendrograms. The color bar indicates that red is the high score (expression or 
infiltration), while green is the low score. 
Figure 3
The patterns of immune cell infiltration into tumor sites in each cluster. 
The dot plots represent the number of immune cells in the four clusters; (A) CD4; (B) 
CD8; (C) CD1α; (D) CD57; (E) FOXP3; and (F) PD-1 (*p<0.05, **p<0.01, 
***p<0.0001).
Figure 4
The patterns of immunosuppressive factor expression in each cluster. 
The dot plots represent the expression levels of immunosuppressive factors in the four 
clusters; (A) PD-L1; (B) PD-L2; (C) TGFβ1; (D) COX-1; and (E) COX-2 (*p<0.05, 
**p<0.01, ***p<0.0001).
Figure 5
Overall survival analyses of patients with ovarian cancer according to the four clusters.
(A) Kaplan–Meier curves according to Cluster 1 and the other clusters. 
(B) Kaplan–Meier curves according to Cluster 1 and the combination of other clusters. 
Supplementary Figure 1
Overall survival analyses of patients with ovarian cancer according to each 
immunological factor.
Kaplan–Meier curves according to the expression of the immunosuppressive factors (A) 
TGFβ1, (B) COX-1, and (C) COX-2 and to the number of (D) CD1α+ cells, (E) CD4+ 
cells, (F) CD57+ cells, (G) FOXP3+ cells and (H) PD-1+ cells infiltrating into tumor 
site
Supplementary Table 1
Primary antibodies used for immunohistochemistry.
*Antigen retrieval: MW, Microwave; PC, Pressure cooker; CB, Citrate Buffer (pH 6.0); 
EDTA, Tris-EDTA buffer (pH 9.0).





PD-L1 27A2 mouse MBL MW (CB) 30
PD-L2 Poly goat R&D systems MW (EDTA) 30
COX-1 160110 mouse Cayman Chemical MW (CB) 44
COX-2 160112 mouse Cayman Chemical MW (CB) 44
TB21 mouse Abcam PC (EDTA)
Immune cell
HI149 mouse Becton Dickinson MW (CB) 44
CD4 1F6 mouse Nichirei PC (EDTA)
CD8 C8/144B mouse Nichirei MW (CB) 30
CD57 HNK-1 mouse Becton Dickinson None 31
PD-1 NAT mouse Abcam PC (CB)
FOXP3 236A/E7 mouse eBioscience PC (CB)
Supplementary Table 2
Correlations between the expression of TGF 1 and clinicopathological characteristics 




<55 32 19 13 0.207
55 38 29 9
Stage 0.883
I 27 21 6
II 4 2 2
III 26 19 7
IV 13 8 5
Histology 0.571
Serous 33 23 10
Clear cell 22 17 5
Endometrioid 11 6 5
Mucinous 2 1 1
Others 2 1 1
Tumor status 0.849
pT1+pT2 31 22 9
pT3 39 26 13
LN metastasis 0.741
Positive 14 9 5
Negative 56 39 17
Distant metastasis 0.593
Positive 13 8 5
Negative 57 40 17
Residual tumor 0.773
  Optimal 49 35 14
  Suboptimal 21 13 8
Chemotherapy 0.732
  No paclitaxel 39 27 12
  Paclitaxel 31 21 10
Supplementary Table 3 
The average numbers of tumor- cells, CD4+cells, CD8+cells, 
CD57+cells, FOXP3+cells or PD-1+ immune cells was counted using the same 70 
ovarian cancer specimens.
Average number Standard Deviation range
CD1a 1.4 6.7 0-18.4
CD4 5.8 6.7 0-44.8
CD8 6.6 8.3 0-56.8
CD57 1.6 1.0 0-5.0
FOXP3 3.3 4.3 0-19
PD-1 1.2 2.5 0-12.6
Supplementary Table 4 
Correlations between tumor-infiltrating CD1 + cells or CD57+ cells and clinicopathological characteristics in 
ovarian cancer (n = 70)
n CD1 + cells p CD4+ cells p CD57+ cells p
Low High Low High Low High
Age 0.072 0.533 0.448
<55 32 22 10 17 15 20 12
55 38 18 20 23 15 27 11
Stage 0.640 0.447 0.438
I 27 15 12 19 8 21 6
II 4 2 2 2 2 1 3
III 26 13 13 14 12 16 10
IV 13 10 3 5 8 9 4
Histology 0.700 0.057 0.973
Serous 33 20 13 13 20 20 13
Clear cell 22 13 9 18 4 15 7
Endometrioid 11 4 7 7 4 8 3
Mucinous 2 0 2 2 0 2 0
Others 2 1 1 0 2 2 0
Tumor status 0.917 0.176 0.725
pT1+pT2 31 17 14 21 10 22 9
pT3 39 23 16 19 20 25 14
LN metastasis 0.131 0.365 0.065
Positive 14 5 9 6 8 6 8
Negative 56 35 21 34 22 41 15
Distant metastasis 0.198 0.231 0.881
Positive 13 10 3 5 8 9 4
Negative 57 30 27 35 22 38 19
Residual tumor 0.792 0.065 0.824
  Optimal 49 27 22 32 17 33 16
  Suboptimal 21 13 8 8 13 14 7
Chemotherapy 0.066 0.071 0.388
  No paclitaxel 39 18 21 26 13 24 15
  Paclitaxel 31 22 9 14 17 23 8
Supplementary Table 5 
Correlations between tumor-infiltrating FOXP3+ cells or PD-1+ cells and 
clinicopathological characteristics in ovarian cancer (n = 70)
n FOXP3+ cells p PD-1+ cells p
Low High Low High
Age 28 42 0.040 48 22 0.976
<55 32 17 15 22 10
55 38 11 27 26 12
Stage 0.055 0.305
I 27 16 11 22 5
II 4 3 1 2 2
III 26 6 20 16 10
IV 13 3 10 8 5
Histology 0.0043 0.999
Serous 33 6 27 24 9
Clear cell 22 16 6 16 6
Endometrioid 11 5 6 8 3
Mucinous 2 1 1 2 0
Others 7 2 0 2 0
Tumor status 0.0027 0.155
pT1+pT2 31 19 12 24 7
pT3 39 9 30 24 15
LN metastasis 0.502 0.949
Positive 14 4 10 10 4
Negative 56 24 32 38 18
Distant metastasis 0.286 0.784
Positive 13 3 10 8 5
Negative 57 25 32 40 17
Residual tumor 0.0069 0.955
  Optimal 49 25 24 33 16
  Suboptimal 21 3 18 15 6
Chemotherapy 0.238 0.515
  No paclitaxel 39 18 21 28 11
  Paclitaxel 31 10 21 20 11

